

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sinopharm Tech Holdings Limited

國藥科技股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8156)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO GRANT OF SHARE OPTIONS

Reference is made to the announcement of Sinopharm Tech Holdings Limited (the “**Company**”) dated 27 August 2021 in relation to the grant of share options (the “**Announcement**”). Unless otherwise specified, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

The Board wishes to provide the shareholders and potential investors of the Company with the following additional information in respect of the grant of the Options. To the best of the knowledge, information and belief of the Directors having made all reasonable enquiries, the identities of the two consultants who were granted with the Options, and the number of Options granted to each of them are as follows:

Lyu Dong (the “**Consultant A**”) is an experienced participant in the Chinese sports lottery industry, the core element of the product in the “anti-counterfeiting device + lottery” business and the main person in charge of the relevant authorized business cooperation suppliers in different provinces across the country, providing continuous and stable supply and customized arrangements for the production of anti-counterfeiting devices to meet the actual business needs. The Company considered that The Consultant A will provide assistance and support to the Group in relation to the above-mentioned related businesses, and provide opinions on the relevant businesses of the Group. The Consultant A was granted with 10,000,000 Options.

Dong Guowei (the “**Consultant B**”) is an experienced industry participant in the research and development and cooperation of Internet financial products. He has provided opinions and support for business implementation in the development of related functions in the “Anti-counterfeiting device + lottery” product. The Company considered that the Consultant B will provide assistance and support to the Group in relation to the above-mentioned related businesses, and provide opinions on the relevant businesses of the Group. At the same time, the Consultant B will provide continuous development support and guidance for the relevant

functions of the “Anti-counterfeiting device + lottery” product, and also assist the Company in expanding its business model and revenue model in related businesses, and tries its best to establish cooperation with potential partners in the market. The Consultant B was granted with 4,000,000 Options.

By order of the Board
Sinopharm Tech Holdings Limited
國藥科技股份有限公司
CHAN Ting
Chairperson

Hong Kong, 2 September 2021

As at the date of this announcement, the Board comprises Mr. CHAN Ting, Mr. LIAO Zhe and Mr. CHEUK Ka Chun Kevin as executive Directors, Madam CHEUNG Kwai Lan and Dr. CHENG Yanjie as non-executive Directors and Mr. LAU Fai Lawrence, Dr. LIU Ta-pei and Mr. CHAU Wai Wah Fred as independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the GEM website at www.hkgem.com for a minimum period of 7 days from the date of its publication and on the website of the Company at www.sinopharmtech.com.hk.